“Journal of the National Cancer Institute” magazine reported the application revised AJCC TNM staging system for residual tumor after neoadjuvant chemotherapy for pathological stage, to predict prognosis of patients with recent results. The study by the University of North Carolina Dr. Carey LA responsible for completing the aim was to assess the new neo-adjuvant chemotherapy for patients with pathological stage the prognosis.
A total of 132 patients with early stage breast cancer patients into the group, accepted the neo-adjuvant chemotherapy and surgical treatment, the median followed up for 5 years. The results showed that 5-year overall survival was 74%, 5-year distant metastasis-free survival was 68%. To accept new patients after adjuvant chemotherapy surgical specimens of pathological stage, and distant metastasis and overall survival in patients with strongly correlated, while the findings also found that the newly revised AJCC TNM staging system, the more NSABP staging system provides better information information, and the implementation of simple, on a more accurate assessment of the prognosis of patients.
The researchers believe that future research should be how to determine the number of cycles of chemotherapy in order to avoid excessive or inadequate chemotherapy.
